VIM
ALNY icon

Vinva Investment Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Vinva Investment Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$11.6M Buy
36,601
+18,640
+104% +$6.34M 0.14% 164
2025
Q4 		$7.14M Buy
17,961
+16,703
+1,328% +$7.39M 0.09% 185
2025
Q3 		$563K Buy
+1,258
New +$512K 0.01% 369

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vinva Investment Management's ALNY Position: Q1 2026 in Review

Vinva Investment Management increased its Alnylam Pharmaceuticals (ALNY) stake by 104% in Q1 2026, buying an estimated $6.34M and bringing the position to 36,601 shares worth $11.6M. The position accounts for 0.14% of the portfolio, ranked #164.

Vinva Investment Management first reported a position in ALNY in Q3 2025 and has held it in 3 quarters since. 789 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

  • Vinva Investment Management held 36,601 shares of Alnylam Pharmaceuticals worth $11.6M as of Q1 2026.
  • Vinva Investment Management bought 18,640 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $6.34M.
  • Alnylam Pharmaceuticals made up 0.14% of Vinva Investment Management's portfolio in Q1 2026, its #164 holding.
  • Vinva Investment Management first reported a position in Alnylam Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • 789 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on Vinva Investment Management's 13F filing for Q1 2026, filed 14 May 2026.